Business Wire

Omnitracs Expands Its Platform Offering With Acquisition of SmartDrive

Share

Omnitracs, LLC, a leader in SaaS-based fleet management and data analytics solutions and a pioneer in transportation technology, and SmartDrive, a leader in video-based safety and transportation intelligence, today announced that they have entered into a definitive agreement for Omnitracs to acquire SmartDrive. The combined company will bring together two transportation technology leaders to offer an industry-first converged, end-to-end platform that optimizes safety, driver productivity and workflow, as well as routing, dispatch and compliance.

Pervasive connectivity, advanced hardware, and the power of artificial intelligence (AI) and machine learning (ML) are just a few of the technology advancements that promise to unlock value and improve efficiency across all aspects of the $60B transportation technology industry. Unlocking that value in the highly fragmented fleet business, however, requires sufficient data and correlation. The new combined company will, for the first time, unite driving context with operational insight across hundreds of billions of data points to transform the experience for the driver, back office, and customer service alike.

“By integrating SmartDrive’s unparalleled transportation intelligence platform, video safety hardware and risk analysis service offering with the Omnitracs One platform, we can deliver a converged solution built on AI and ML that redefines the future of commercial transportation today. Real-time risk mitigation, streamlined data flows from the cab and vehicle sensors to dispatch and the back office, and a superior driver experience will be brought together to improve safety, efficiency and operational excellence,” said Ray Greer, Chief Executive Officer, Omnitracs. “We have long admired SmartDrive’s customer-centric approach to technology innovation and world class support and service. We look forward to welcoming the talented SmartDrive team to the Omnitracs family.”

There is no one-size-fits all solution for today’s fleets: the needs of oil and gas operations are very different from those of general freight – and both differ from local delivery and dozens of other transportation operations. Both Omnitracs and SmartDrive have built their businesses around providing enterprise-grade, flexible and adaptive solutions that can anticipate and address the distinct operating requirements of each fleet they serve. Together, their depth of experience across decades of partnerships will enable the combined company to uniquely support complexity at scale.

“We couldn’t be more excited about joining forces with Omnitracs and look forward to realizing and advancing the promise of convergence to the benefit of our shared customers,” stated Steve Mitgang, Chief Executive Officer, SmartDrive. “In Omnitracs, we have a like-minded company, seeing the power of data for innovation and solving material fleet and transportation industry challenges.”

The COVID-19 pandemic has underscored the significant role of commercial drivers, as the trucking sector has been instrumental to ensuring the availability of critical medical supplies and equipment, as well as essential consumer goods. Given the long-standing shortage of qualified drivers and high turnover rates, creating and sustaining a favorable driver experience (DX) is imperative to fleets’ success. However, recent transportation technology advancements have resulted in a proliferation of devices and sensors, the need for multiple cellular connections, siloed data streams that create redundancies, and other inefficiencies that stem from disparate onboard and back-office systems, all of which complicated the DX.

SmartDrive’s proven video-based safety program integrated with Omnitracs’ best-in-class driver workflow and complemented by the companies’ unmatched years of collective transportation intelligence present an opportunity to streamline and enhance DX. The combined company will deliver the most complete and intelligent DX with the right in-cab and back-office decision making, alerting, and driver coaching – a virtual co-pilot that will lead to significant safety, fuel efficiency, operational and financial gains for fleets.

“We’ve had great partnerships with both Omnitracs and SmartDrive over the years. We are excited to see these two companies come together,” said Chad England, Chief Executive Officer, C.R. England, Inc. “We are confident that the integration of offerings will create efficiencies for C.R. England. We congratulate both Omnitracs and SmartDrive on their new relationship and look forward to the future.”

Subject to customary closing conditions, including customary regulatory approval, the deal is expected to close later in calendar Q3 or Q4. Kirkland & Ellis LLP advised Omnitracs on the acquisition. PJT Partners is serving as exclusive financial advisor and Pillsbury Winthrop Shaw Pittman LLP is serving as legal counsel to SmartDrive.

About SmartDrive

SmartDrive Systems gives fleets and drivers unprecedented driving performance insight and analysis, helping save fuel, expenses and lives. Its video safety, predictive analytics, telematics, compliance and personalized performance program help fleets improve driving skills, lower operating costs and deliver significant ROI. With an easy-to-use managed service, fleets and drivers can access and self-manage driving performance anytime, anywhere. The company, which is ranked as one of the fastest growing companies by Deloitte’s Technology Fast 500™ for six consecutive years, has recorded nearly 25 billion miles and compiled the world’s largest storehouse of more than 300 million analyzed risky-driving events. SmartDrive Systems is based in San Diego, Calif., and employs over 725 people worldwide.

About Omnitracs, LLC

Omnitracs, LLC is the global pioneer of trucking solutions for all business models. Omnitracs’ more than 1,100 employees deliver software-as-a-service-based solutions to help over 14,000 customers manage nearly 1,100,000 assets in more than 70 countries. The company pioneered the use of commercial vehicle telematics 35 years ago and serves today as a powerhouse of innovative, intuitive technologies. Omnitracs transforms the transportation industry through technology and insight, featuring best-in-class solutions for compliance, safety and security, productivity, telematics and tracking, transportation management (TMS), planning and delivery, data and analytics, and professional services.

Contact information

Kimberly Smiley
Omnitracs
(214) 534-0410
ksmiley@omnitracs.com

Emily Holt
PAN Communications
(781) 635-2336
eholt@pancomm.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a

A Continuous Journey of Digital Transformation, Alibaba Cloud and Its Global Customers at Apsara 202018.9.2020 06:00:00 EESTPress release

As the digital technology and intelligence backbone of Alibaba Group, Alibaba Cloud is experiencing continuous growth alongside its customers across different parts of the world. Over the years, it has made relentless efforts to serve clients from every industry, helping them accelerate their business development and navigate the challenges of these volatile times. Cloud computing and AI technology have been shown to be the cornerstone for businesses seeking to be fully equipped in the digital era, especially following the global outbreak of COVID-19. At the 12th Apsara Conference: Leap into the Future of Digital Intelligence, customers from various sectors, including aviation, leisure and hospitality, education, and e-commerce and retail, share their growth and success stories achieved together with Alibaba Cloud. “It is our utmost pleasure to see our customers experience a seamless transition into more digitalised operations,” said Selina Yuan, President for International Business, A

BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer18.9.2020 01:05:00 EESTPress release

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the first reported data from RATIONALE 304, the Phase 3 trial of its anti-PD-1 antibody tislelizumab in combination with chemotherapy as a potential first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC), and the first reported data from the pivotal Phase 2 trial of its investigational PARP inhibitor pamiparib in advanced ovarian cancer (OC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which takes place on September 19-21. “We are pleased to share the promising RATIONALE 304 results, which were used to support our recently accepted supplemental new drug application in first-line non-squamous NSCLC in China,” commented Yong (Ben) Ben, M.D., Chief Medical Officer, Immuno-Oncology at BeiGene. “BeiGene is evaluating tislelizuma

Sensorion Launches a Capital Increase by Means of an Accelerated Bookbuild Offering17.9.2020 20:33:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, intends to issue new ordinary shares of a nominal value of €0.10 (the “New Shares”) for a total capital increase of approximately €30 million (US$35 million), by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The New Shares will be issued through a share capital increase without shareholders’ preferential subscription rights pursuant to the 12th resolution of the extraordinary general meeting of shareholders of the Company held on May 20, 2020 and in accordance with Article

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom